# Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer

> **NCT00308529** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 55 (—)

## Conditions studied

- Carcinoma, Small Cell Lung
- Lung Cancer

## Interventions

- **DRUG:** irinotecan
- **DRUG:** carboplatin
- **DRUG:** bevacizumab
- **PROCEDURE:** Radiation Therapy

## Key facts

- **NCT ID:** NCT00308529
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2007-04
- **Final completion:** 2009-01
- **Target enrollment:** 55 (—)
- **Last updated:** 2010-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00308529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00308529, "Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00308529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*